Hydromorphone side effects: what 91,449 FDA adverse event reports show
Drug class
Not stated in label
Label matched
Hydromorphone Hydrochloride (Hydromorphone Hydrochloride)
Who reports
91,449 reports · 93% serious · 28,105 with death outcome · 52% female
Used for
Hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Hydromorphone hydrochloride ora.
What it is
Hydromorphone is a morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.
Boxed warning
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE See full prescribing information for complete boxed warning . Ensure accuracy when prescribing, dispensing, and administering hydromorphone hydrochloride oral solution.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,185 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Vaginal flatulence | 224 | 646.9 500.0–837.0ROR 648.5 · calibrated p 9e-15 ✓ | 165.5 EB05 148.1 · IC025 +6.7 3/3 methods agree | Not in label — unassessed | serious n=224 · ♀ 100% (drug 52%) | no trial arm names this drug |
| Antacid therapy | 69 | 310.9 216.0–447.3ROR 311.1 · calibrated p 3e-11 ✓ | 126.7 EB05 103.5 · IC025 +5.7 3/3 methods agree | Reporting / coding artifact | serious n=69 · ♀ 0% (drug 52%) · 100% clinician | no trial arm names this drug |
| Sleep disorder therapy | 98 | 256.7 192.2–342.9ROR 257.0 · calibrated p 1e-10 ✓ | 117.8 EB05 99.5 · IC025 +5.9 3/3 methods agree | Reporting / coding artifact | serious n=98 · ♀ 0% (drug 52%) · 100% clinician | no trial arm names this drug |
| Appendicolith | 166 | 178.9 145.9–219.3ROR 179.2 · calibrated p 1e-9 ✓ | 99.0 EB05 87.0 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious n=166 · ♀ 0% (drug 52%) · 100% clinician | no trial arm names this drug |
| Inspiratory capacity decreased | 95 | 120.9 94.2–155.1ROR 121.0 · calibrated p 4e-8 ✓ | 77.8 EB05 65.6 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=95 · ♀ 0% (drug 52%) · 100% clinician | no trial arm names this drug |
| Analgesic therapy | 102 | 114.3 90.1–145.1ROR 114.4 · calibrated p 6e-8 ✓ | 75.1 EB05 63.7 · IC025 +5.5 3/3 methods agree | Reporting / coding artifact | serious n=102 · ♀ 0% (drug 52%) · 100% clinician | no trial arm names this drug |
| Drug therapy | 102 | 107.4 84.8–135.9ROR 107.5 · calibrated p 1e-7 ✓ | 72.1 EB05 61.1 · IC025 +5.4 3/3 methods agree | Reporting / coding artifact | serious n=102 · ♀ 0% (drug 52%) · 100% clinician | no trial arm names this drug |
| Learning disability | 1,551 | 92.6 87.3–98.2ROR 94.2 · calibrated p 2e-7 ✓ | 65.9 EB05 63.1 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious n=1,548 · 100% consumer | no trial arm names this drug |
| Neonatal hypoacusis | 63 | 84.0 62.9–112.1ROR 84.0 · calibrated p 7e-7 ✓ | 60.4 EB05 48.9 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=63 · 100% consumer | no trial arm names this drug |
| Vision abnormal neonatal | 109 | 79.5 63.9–98.8ROR 79.6 · calibrated p 8e-7 ✓ | 58.4 EB05 49.8 · IC025 +5.2 3/3 methods agree | Labeled (related wording) related wording | serious n=109 · 100% consumer | no trial arm names this drug |
| Anticoagulant therapy | 67 | 72.9 55.4–96.0ROR 73.0 · calibrated p 2e-6 ✓ | 54.5 EB05 44.4 · IC025 +4.9 3/3 methods agree | Reporting / coding artifact | serious n=67 · ♀ 0% (drug 52%) · 100% clinician | no trial arm names this drug |
| Congenital hiatus hernia | 52 | 70.1 51.4–95.7ROR 70.2 · calibrated p 2e-6 ✓ | 52.7 EB05 41.8 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=52 · ♀ 0% (drug 52%) · 100% clinician | no trial arm names this drug |
| Malignant melanoma stage 0 | 41 | 66.9 47.2–94.8ROR 67.0 · calibrated p 4e-6 ✓ | 50.7 EB05 38.9 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=41 · ♀ 0% (drug 52%) · 100% clinician | no trial arm names this drug |
| Drug dependence | 35,112 | 63.1 62.4–63.7ROR 101.7 · calibrated p 1e-7 ✓ | 49.5 EB05 49.1 · IC025 +5.6 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 30.3 · serious PRR 31.4 · 96% consumer | no trial arm names this drug |
| Drug withdrawal syndrome neonatal | 2,771 | 52.1 50.0–54.2ROR 53.7 · calibrated p 9e-6 ✓ | 42.5 EB05 41.2 · IC025 +5.3 3/3 methods agree | Labeled (related wording) related wording | serious PRR 26.4 · 100% consumer | no trial arm names this drug |
| Drug withdrawal syndrome | 14,329 | 44.1 43.4–44.8ROR 52.1 · calibrated p 1e-5 ✓ | 37.0 EB05 36.5 · IC025 +5.2 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 11.1 · serious PRR 28.7 · 85% consumer | no trial arm names this drug |
| Substance dependence | 103 | 41.6 33.7–51.3ROR 41.6 · calibrated p 5e-5 ✓ | 35.0 EB05 29.7 · IC025 +4.6 3/3 methods agree | Labeled (related wording) related wording | serious n=103 · 100% consumer | no trial arm names this drug |
| Temperature regulation disorder | 334 | 41.3 36.7–46.4ROR 41.4 · calibrated p 4e-5 ✓ | 35.0 EB05 31.9 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=333 · ♀ 100% (drug 52%) | no trial arm names this drug |
| Developmental delay | 1,388 | 41.2 38.9–43.6ROR 41.8 · calibrated p 4e-5 ✓ | 35.0 EB05 33.4 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious PRR 22.0 · 100% consumer | no trial arm names this drug |
| Emotional distress | 17,705 | 39.0 38.5–39.6ROR 48.2 · calibrated p 2e-5 ✓ | 33.4 EB05 33.0 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 5.5 · serious PRR 22.9 · 91% consumer | no trial arm names this drug |
| Female genital tract fistula | 242 | 37.4 32.7–42.9ROR 37.5 · calibrated p 8e-5 ✓ | 32.2 EB05 28.9 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=242 · ♀ 100% (drug 52%) | no trial arm names this drug |
| Amaurosis fugax | 143 | 35.3 29.6–42.1ROR 35.3 · calibrated p 1e-4 ✓ | 30.5 EB05 26.6 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=143 · 100% clinician | no trial arm names this drug |
| Self esteem decreased | 309 | 33.2 29.4–37.4ROR 33.3 · calibrated p 2e-4 ✓ | 29.0 EB05 26.4 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=309 · 100% consumer | no trial arm names this drug |
| Retinitis | 203 | 31.6 27.3–36.6ROR 31.7 · calibrated p 2e-4 ✓ | 27.8 EB05 24.7 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=203 · ♀ 100% (drug 52%) · 100% clinician | no trial arm names this drug |
| Soft tissue disorder | 124 | 28.5 23.6–34.4ROR 28.5 · calibrated p 4e-4 ✓ | 25.3 EB05 21.8 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=123 · ♀ 100% (drug 52%) | no trial arm names this drug |
| Overdose | 23,060 | 27.2 26.9–27.6ROR 36.1 · calibrated p 9e-5 ✓ | 24.4 EB05 24.1 · IC025 +4.6 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 7.4 · serious PRR 19.1 · 89% consumer | no trial arm names this drug |
| Radiculopathy | 265 | 25.5 22.5–29.0ROR 25.6 · calibrated p 6e-4 ✓ | 23.0 EB05 20.8 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=263 · ♀ 94% (drug 52%) | no trial arm names this drug |
| Drug tolerance increased | 75 | 24.1 19.0–30.6ROR 24.2 · calibrated p 9e-4 ✓ | 21.8 EB05 18.0 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious n=69 · 100% consumer | no trial arm names this drug |
| Lupus vulgaris | 110 | 23.3 19.1–28.3ROR 23.3 · calibrated p 0.001 ✓ | 21.1 EB05 18.0 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=110 · ♀ 100% (drug 52%) · 100% clinician | no trial arm names this drug |
| Nasal oedema | 159 | 22.2 18.9–26.2ROR 22.3 · calibrated p 0.001 ✓ | 20.3 EB05 17.8 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=159 · ♀ 100% (drug 52%) · 100% clinician | no trial arm names this drug |
| Proctitis | 235 | 20.9 18.3–23.9ROR 21.0 · calibrated p 0.002 ✓ | 19.2 EB05 17.2 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=235 · ♀ 100% (drug 52%) | no trial arm names this drug |
| Hypermobility syndrome | 41 | 20.6 15.0–28.4ROR 20.6 · calibrated p 0.002 ✓ | 18.8 EB05 14.4 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=41 · ♀ 100% (drug 52%) · 100% clinician | no trial arm names this drug |
| Substance use disorder | 247 | 19.9 17.5–22.7ROR 20.0 · calibrated p 0.002 ✓ | 18.4 EB05 16.5 · IC025 +3.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=247 · 100% consumer | no trial arm names this drug |
| Medical device site pain | 44 | 19.4 14.3–26.4ROR 19.4 · calibrated p 0.003 ✓ | 17.8 EB05 13.8 · IC025 +3.4 3/3 methods agree | Labeled (related wording) related wording | – | no trial arm names this drug |
| Imprisonment | 140 | 19.4 16.3–23.0ROR 19.4 · calibrated p 0.002 ✓ | 17.9 EB05 15.5 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=140 · ♀ 31% (drug 52%) · 100% consumer | no trial arm names this drug |
| Implant site extravasation | 61 | 19.1 14.7–24.8ROR 19.1 · calibrated p 0.003 ✓ | 17.6 EB05 14.1 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=50 | no trial arm names this drug |
| Chronic sinusitis | 267 | 17.5 15.5–19.9ROR 17.6 · calibrated p 0.004 ✓ | 16.3 EB05 14.7 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=267 · ♀ 100% (drug 52%) | no trial arm names this drug |
| Bone erosion | 251 | 17.4 15.3–19.8ROR 17.5 · calibrated p 0.004 ✓ | 16.2 EB05 14.6 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=251 · ♀ 100% (drug 52%) · 93% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 47 | 17.3 12.9–23.3ROR 17.3 · calibrated p 0.005 ✓ | 16.0 EB05 12.4 · IC025 +3.3 3/3 methods agree | Lab value / disease marker | serious n=47 · ♀ 100% (drug 52%) · 100% clinician | no trial arm names this drug |
| Spina bifida | 141 | 16.4 13.8–19.5ROR 16.4 · calibrated p 0.005 ✓ | 15.3 EB05 13.3 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=141 · 100% consumer | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Dependence / withdrawal | 36,625 | 32.332.0–32.6 | signal |
| Depression | 3,033 | 2.52.4–2.6 | signal |
| Serious infection | 4,844 | 1.41.4–1.5 | raised |
| Hyponatraemia | 502 | 1.41.3–1.6 | raised |
| Suicidality | 1,470 | 1.41.3–1.4 | raised |
| Venous thromboembolism | 1,287 | 1.41.3–1.4 | raised |
| Liver injury | 1,739 | 1.31.3–1.4 | raised |
| Anaemia | 1,618 | 1.21.2–1.3 | raised |
| Fall / fracture | 1,920 | 1.21.1–1.2 | raised |
| Pancreatitis | 404 | 1.11.0–1.3 | raised |
| Gi bleeding | 915 | 1.11.1–1.2 | raised |
| Thrombocytopenia | 1,008 | 1.01.0–1.1 | no difference |
| Opportunistic infection | 594 | 1.00.9–1.1 | no difference |
| Tendon disorder | 153 | 0.90.8–1.1 | no difference |
| Seizure | 733 | 0.90.8–0.9 | lower than other drugs |
| Anaphylaxis / angioedema | 461 | 0.80.8–0.9 | lower than other drugs |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug dependence | 35,112 | 63.1 62.4–63.7ROR 101.7 · calibrated p 1e-7 ✓ | 49.5 EB05 49.1 · IC025 +5.6 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 30.3 · serious PRR 31.4 · 96% consumer | no trial arm names this drug |
| Overdose | 23,060 | 27.2 26.9–27.6ROR 36.1 · calibrated p 9e-5 ✓ | 24.4 EB05 24.1 · IC025 +4.6 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 7.4 · serious PRR 19.1 · 89% consumer | no trial arm names this drug |
| Pain | 22,286 | 8.6 8.5–8.7ROR 11.0 · calibrated p 0.023 ✓ | 8.3 EB05 8.2 · IC025 +3.0 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 5.2 · serious PRR 7.9 | no trial arm names this drug |
| Emotional distress | 17,705 | 39.0 38.5–39.6ROR 48.2 · calibrated p 2e-5 ✓ | 33.4 EB05 33.0 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 5.5 · serious PRR 22.9 · 91% consumer | no trial arm names this drug |
| Death | 14,911 | 4.0 4.0–4.1ROR 4.6 · calibrated p 0.281 | 4.0 EB05 3.9 · IC025 +2.0 3/3 methods agree | Outcome field, not a reaction boxed warning mentions mortality | age-adj. PRR 1.5 · serious PRR 2.5 · 79% consumer | no trial arm names this drug |
| Drug withdrawal syndrome | 14,329 | 44.1 43.4–44.8ROR 52.1 · calibrated p 1e-5 ✓ | 37.0 EB05 36.5 · IC025 +5.2 3/3 methods agree | Labeled (related wording) related wording | age-adj. PRR 11.1 · serious PRR 28.7 · 85% consumer | no trial arm names this drug |
| Toxicity to various agents | 10,081 | 14.6 14.3–14.9ROR 16.3 · calibrated p 0.005 ✓ | 13.8 EB05 13.5 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | age-adj. PRR 3.1 · serious PRR 8.8 | no trial arm names this drug |
| Nausea | 4,758 | 1.4 1.3–1.4ROR 1.4 · calibrated p 0.579 | 1.4 EB05 1.4 · IC025 +0.4 | Labeled adverse reaction exact term | age-adj. PRR 3.1 · serious PRR 1.4 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 4,474 | 0.8 0.8–0.8ROR 0.8 · calibrated p 0.165 | 0.8 EB05 0.8 · IC025 -0.4 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 2.2 · serious PRR 1.2 · ♀ 74% (drug 52%) | no trial arm names this drug |
| Fatigue (tiredness) | 3,617 | 1.1 1.0–1.1ROR 1.1 · calibrated p 0.353 | 1.1 EB05 1.0 · IC025 +0.0 | Labeled adverse reaction exact term | age-adj. PRR 2.6 · serious PRR 1.1 | no trial arm names this drug |
| Vomiting | 3,530 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.807 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 3.9 · serious PRR 1.5 · ♀ 73% (drug 52%) | no trial arm names this drug |
| Off label use (used outside approved label) | 3,414 | 0.9 0.9–0.9ROR 0.9 · calibrated p 0.242 | 0.9 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 2.2 · serious PRR 1.0 | no trial arm names this drug |
| Anxiety | 3,385 | 2.7 2.7–2.8ROR 2.8 · calibrated p 0.692 | 2.7 EB05 2.6 · IC025 +1.4 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 3.2 · serious PRR 2.2 | no trial arm names this drug |
| Drug abuse | 3,120 | 8.8 8.5–9.2ROR 9.1 · calibrated p 0.044 ✓ | 8.5 EB05 8.3 · IC025 +3.0 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 4.2 · serious PRR 5.4 · 85% consumer | no trial arm names this drug |
| Headache | 3,022 | 1.1 1.1–1.1ROR 1.1 · calibrated p 0.380 | 1.1 EB05 1.1 · IC025 +0.1 | Labeled adverse reaction exact term | age-adj. PRR 2.4 · serious PRR 1.3 · ♀ 81% (drug 52%) | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Vaginal flatulence — n=224, PRR 646.9
- Appendicolith — n=166, PRR 178.9
- Inspiratory capacity decreased — n=95, PRR 120.9
- Learning disability — n=1,551, PRR 92.6
- Neonatal hypoacusis — n=63, PRR 84.0
- Congenital hiatus hernia — n=52, PRR 70.1
- Malignant melanoma stage 0 — n=41, PRR 66.9
- Temperature regulation disorder — n=334, PRR 41.3
- Developmental delay — n=1,388, PRR 41.2
- Emotional distress — n=17,705, PRR 39.0
✓ A hand-written Bradford Hill causality assessment exists for this drug: Hydromorphone ↔ Drug dependence.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Hydromorphone?
In FDA FAERS, the most frequently co-reported reaction terms for Hydromorphone are pain, emotional distress, drug withdrawal syndrome, toxicity to various agents, nausea, fatigue. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Hydromorphone have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROMORPHONE HYDROCHLORIDE See full prescribing information for complete boxed warning . Ensure accuracy when prescribing, dispensing, and administering hydromorphone hydrochloride oral solution.
Do FAERS signals prove that Hydromorphone causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 18f6f54e-1537-4181-9d07-54ddf881a9ee, effective 20251204; matched on
openfda.generic_name.exact:"HYDROMORPHONE HYDROCHLORIDE") - PubChem CID 5284570 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,225 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
HYDROMORPHONE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.